🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT06742437
Recruiting Observational

Efficacy and Safety of a New Sperm Capacitation Method

NCT06742437 · tracked via the Priya Life Science Spain tracker
Sponsor
Fecundis Lab SL
Phase
Observational
Started
2025-01-14
Last updated
2026-09-01

Condition(s) studied

Reproductive IssuesMale InfertilityAsthenozoospermiaOligozoospermiaTeratozoospermia

Investigational drug(s) / intervention(s)

Standard sperm preparationHyperSperm

Standard sperm preparation: Sperm samples in the control group will undergo traditional processing

HyperSperm: Sperm samples in the experimental group will undergo product-specific processing

Study summary

Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to evaluate the efficacy and safety of HyperSperm, a new sperm capacitation method, in 300 semen samples with various characteristics and abnormalities, in an in vitro study over 12 months.

Eligibility

Sex
MALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Ability to provide a semen sample via masturbation Exclusion Criteria: * Current diagnosis of a sexually transmitted infection (STI) * Previous diagnosis of hepatitis A, B, C, D, or HIV * Prior participation in this study * Participation in a clinical trial involving an intervention within the last 3 months

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Eugin Barcelona Barcelona Barcelona Recruiting
Fertty Barcelona Barcelona Recruiting
CIRH Barcelona Barcelona Recruiting
Natuvitro Barcelona Barcelona Recruiting

More Fecundis Lab SL trials in Spain

Development of an AI Platform for the Analysis of Sperm and Prediction of Their Clinical Potential Recruiting

Other trials for the same condition

Development of an AI Platform for the Analysis of Sperm and Prediction of Their Clinical Potential Recruiting
Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress Recruiting
Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06742437 on ClinicalTrials.gov ↗ ← All trials in Spain